Bicarbonate

Bicarbonate

SCHEMBL331955

O.O=C(O)O.O=C(O)O.[LiH]

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.71
CA2 P00918 1/20 0.71
CA9 Q16790 1/20 0.71
FFAR3 O14843 2/20 0.40
ACHE P22303 1/20 0.40
LCK P06239 1/20 0.40
FYN P06241 1/20 0.40
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
TSHR P16473 4/20 0.33
LDHA P00338 2/20 0.33
EGLN1 Q9GZT9 2/20 0.33
LDHB P07195 1/20 0.33
SRR Q9GZT4 1/20 0.33
TP53 P04637 1/20 0.33
LMNA P02545 1/20 0.33
ALKBH5 Q6P6C2 1/20 0.33
SUCNR1 Q9BXA5 1/20 0.33
EGLN3 Q9H6Z9 1/20 0.33
OR51E2 Q9H255 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL22187750 1.00
Bicarbonate SCHEMBL6049034 1.00
Bicarbonate SCHEMBL28583072 1.00 CA1 (0.71) CA1CA2CA9FFAR3ACHE
Bicarbonate SCHEMBL28853717 1.00
Bicarbonate SCHEMBL2639598 0.94 CA1 (0.62) CA1CA2CA9FFAR3ACHE
Bicarbonate SCHEMBL4306718 0.94
Bicarbonate SCHEMBL2639602 0.94
Bicarbonate SCHEMBL5572362 0.94
Bicarbonate SCHEMBL5251123 0.94
Bicarbonate SCHEMBL28213934 0.94

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10435351-B2 Enamide process SUNOVION PHARMACEUTICALS INC. (US) 2019-10-08 US disclosed
WO-2018144385-A1 ENAMIDE PROCESS SUNOVION PHARMACEUTICALS INC. (US) 2018-08-09 WO disclosed
US-20180215702-A1 ENAMIDE PROCESS SUNOVION PHARMACEUTICALS INC. 2018-08-02 US disclosed
US-10011559-B2 Preparation of chiral amides and amines SUNOVION PHARMACEUTICALS INC. (US) 2018-07-03 US disclosed
US-20180016224-A1 PREPARATION OF CHIRAL AMIDES AND AMINES SUNOVION PHARMACEUTICALS INC. 2018-01-18 US disclosed
EP-2816024-B1 Chiral amines SUNOVION PHARMACEUTICALS INC (US) 2017-08-02 EP disclosed
US-20160016891-A1 PREPARATION OF CHIRAL AMIDES AND AMINES SUNOVION PHARMACEUTICALS INC. 2016-01-21 US disclosed
EP-2013835-B1 PREPARATION OF CHIRAL AMIDES AND AMINES SUNOVION PHARMACEUTICALS INC (US) 2015-11-04 EP disclosed
EP-2816024-A1 Chiral amines Sunovion Pharmaceuticals Inc. (US) 2014-12-24 EP disclosed
US-20140057990-A1 PREPARATION OF CHIRAL AMIDES AND AMINES SUNOVION PHARMACEUTICALS INC. (US) 2014-02-27 US disclosed
US-8524950-B2 Preparation of chiral amides and amines SUNOVION PHARMACEUTICALS INC. (US) 2013-09-03 US disclosed
US-20120095106-A1 PREPARATION OF CHIRAL AMIDES AND AMINES SUNOVION PHARMACEUTICALS INC. (US) 2012-04-19 US disclosed
US-8097760-B2 Preparation of chiral amides and amines Sunovion Pharmacuticals Inc. (US) 2012-01-17 US disclosed
US-20090149549-A1 PREPARATION OF CHIRAL AMIDES AND AMINES SUNOVION PHARMACEUTICALS INC. 2009-06-11 US disclosed
EP-2013835-A2 PREPARATION OF CHIRAL AMIDES AND AMINES Sepracor Inc. (US) 2009-01-14 EP disclosed
WO-2007115185-A2 PREPARATION OF CHIRAL AMIDES AND AMINES SEPRACOR INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10011559-B2 Preparation of chiral amides and amines PNMT, ALKBH5, ALKBH2 CA1 425/4885CA2 1010/4885CA9 1175/4885
US-20180016224-A1 PREPARATION OF CHIRAL AMIDES AND AMINES PNMT, ALKBH2, ALKBH5 CA1 407/4885CA2 951/4885CA9 953/4885
US-20160016891-A1 PREPARATION OF CHIRAL AMIDES AND AMINES PNMT, ALKBH5, ALKBH2 CA1 425/4885CA2 1010/4885CA9 1175/4885
US-20090149549-A1 PREPARATION OF CHIRAL AMIDES AND AMINES PNMT, ALKBH5, ALKBH2 CA1 425/4885CA2 1010/4885CA9 1175/4885
US-20120095106-A1 PREPARATION OF CHIRAL AMIDES AND AMINES PNMT, ALKBH5, ALKBH2 CA1 425/4885CA2 1010/4885CA9 1175/4885
US-20180215702-A1 ENAMIDE PROCESS ENO1, ENY2, ALKBH2 CA1 1028/4885CA2 1138/4885CA9 727/4885
US-10435351-B2 Enamide process ENO1, ENY2, ALKBH2 CA1 1028/4885CA2 1138/4885CA9 727/4885
US-20140057990-A1 PREPARATION OF CHIRAL AMIDES AND AMINES PNMT, ALKBH5, ALKBH2 CA1 425/4885CA2 1010/4885CA9 1175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.